Fulvestrant 500mg Versus Exemestane in Postmenopausal Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-Steroidal Aromatase Inhibitors (NSAI) in Clinical Practice – A Multicenter Retrospective Study

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2019.01.015
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Review of Hormone-Based Treatments in Postmenopausal Patients With Advanced Breast Cancer Focusing on Aromatase Inhibitors and Fulvestrant

ESMO Open
Cancer ResearchOncology
2016English

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2012English

Pcn180 - Pharmacoeconomic Assessment of Fulvestrant Versus Dd (Doxorubicin, Docetaxel) Therapy in Postmenopausal Women With Metastatic Er (+) Her2 (-) Breast Cancer in Ukraine

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2003English

A Retrospective Study of Trifluridine/Tipiracil in Pretreated Metastatic Colorectal Cancer Patients in Clinical Practice

Colorectal Cancer
OncologyGastroenterology
2018English

Efficacy of Adjuvant Aromatase Inhibitor in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients According to the Body Mass Index

British Journal of Cancer
Cancer ResearchOncology
2012English

Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer

Breast Care
SurgeryOncology
2008English

Auricular Point Acupressure to Manage Aromatase Inhibitor–Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study

Oncology Nursing Forum
Oncology
2017English

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy